Trial Profile
Efficacy and safety of Apatinib Mesylate for recurrent glioblastoma patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 27 Oct 2017 New trial record